Lava Therapeutics announces collaboration with Merck & co., inc., Rahway, NJ, USA to evaluate Lava-1207 in combination with Keytruda®

by Ysios Capital

Collaboration will support the initiation of a combination arm in the ongoing Phase 1/2a trial in patients with mCRPC

Read more

Ysios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ

by Ysios Capital

Ysios Capital, a leading Spanish biotechnology venture capital firm, today announced that its portfolio company CVRx Inc. has priced its initial public offering (IPO) and is trading on the Nasdaq Glob...

Read more

LAVA Therapeutics Announces $83 million Series C Financing to Advance Novel Immuno-Oncology Programs

by Ysios Capital

LAVA Therapeutics, a biotech company pioneering the development of bispecific antibodies to engage gamma-delta T cells for cancer therapies, today announced the closing of an oversubscribed $83 millio...

Read more
Subscribe to Directory
Write an Article

Recent News

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Tuneable reverse photochromes in the sol...

A new technique allows the design of solid materia...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

The Bigas Lab finds Notch self-inhibitio...

by IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

It has been found that the population of haematopoietic stem cells (HS...

Photos Stream